Close Menu

NEW YORK – Sotio, a clinical stage biotechnology firm based in Prague, has paid $8.1 million upfront to acquire Unum Therapeutics' BOXR cell-based therapy platform and lead programs.

The company said on Monday that it is planning to use Unum's BOXR assets and R&D data to advance CAR T-cell therapies for solid tumors. Under the terms of the deal, Cambridge, Massachusetts-based Unum may also be entitled to $3.4 million in milestone payments.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.